**Thyroid**

**Treatment**

**DTC**
- **END0026**
  Phase II XL184 (Cabozantinib) in Combo w/ Nivolumab and Ipilimumab (CaboNivo) in Thyroid Cancer
  PI: Khan
  Stanford

**ATC/UTC**
- **END0021**
  Phase III Cabozantinib (XL184) in Radiocldine-Refactory Differentiated Thyroid Cancer
  PI: Colevas
  Sponsor: Exelixis

- **END0023**
  Atebraciclib in metastatic or locally advanced Anaplastic/Undifferentiated Thyroid Cancer
  PI: Khan
  Stanford

- **END0025**
  Phase II Pembrolizumab in Metastatic / Locally Advanced Anaplastic / Undifferentiated Thyroid Cancer
  PI: Khan
  Stanford

**KEY**
- **Pending**
- **Open for Enrollment**
- **Link**
- **Trial Posting**
- **Extension Study**
- **Immunotherapy**
- **Optional Path**
- **Observational Study**
- **Enrollment on Hold**

*Please mark up a copy using black ink and email changes to SRC-office@stanford.edu*